Silexion Therapeutics Corp (NASDAQ:SLXN) shares, rose in value, with the stock price down by -11.20% to the previous day’s close as strong demand from buyers drove the stock to $0.81.
Actively observing the price movement in the recent trading, the stock is buoying the session at $0.91, falling within a range of $0.7901 and $0.8599. The value of beta (5-year monthly) is 0.116. Referring to stock’s 52-week performance, its high was $122.02, and the low was $0.57. On the whole, SLXN has fluctuated by -13.52% over the past month.
With the market capitalization of Silexion Therapeutics Corp currently standing at about $7.02 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SLXN’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of SLXN currently trading nearly -2.48% and -11.38% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.43, while the 7-day volatility ratio is showing 7.27% which for the 30-day chart, stands at 5.76%. Furthermore, Silexion Therapeutics Corp (SLXN)’s beta value is 0.05.
A comparison of Silexion Therapeutics Corp (SLXN) with its peers suggests the former has fared considerably weaker in the market. SLXN showed an intraday change of -11.20% in today’s session so far, and over the past year, it shrunk by -59.80%%.
Data on historical trading for Silexion Therapeutics Corp (NASDAQ:SLXN) indicates that the trading volumes over the past 10 days have averaged 1.21 and over the past 3 months, they’ve averaged 1.81 million. According to company’s latest data on outstanding shares, there are 8.69 million shares outstanding.
Nearly 9.05% of Silexion Therapeutics Corp’s shares belong to company insiders and institutional investors own 10.41% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.32 million shares as on 2025-06-13, resulting in a short ratio of 0.29. According to the data, the short interest in Silexion Therapeutics Corp (SLXN) stood at 384.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 0.42 million. The stock has fallen by -99.20% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLXN stock heading into the next quarter.
